Gisela. Sitbon

UU Invest är en tidig investerare med längre exitstrategi jämfört med många andra riskkapitalbolag. UU Invest bistår forskare och studenter att validera teknik, marknad och affärsmodell och investerar även i projekt innan bolagen är bildade. Ett samarbete med UU Invest innebär ett långsiktigt engagemang och tillgång till ett brett nätverk med kompetens och kapital. Genom UU Invest medverkar Uppsala universitet till att etablera nya forskningsbaserade företag. Sedan starten 1995 har UU Invest investerat över 100 MSEK i fler än 100 företag. Idag är UU Invest delägare i mer än 40 företag inom varierande branscher. English: UU Invest AB is an early investor that offers pre-seed and seed capital that makes it possible for researchers and entrepreneurs to further develop their research so that it can directly benefit society. With our early support, we contribute to the companys efforts to build the right business model, create a team with important skills and test their idea on the market. We invest long-term to give companies time to grow slowly, to develop their business and to build teams that can take cutting-edge expertise and technology further. Our involvement in the companies extends from the first investment to 5-15 years beyond.

At InSingulo, we specialize in the characterization of drug interactions with complex targets down to the single molecule level. Our biosensing technology allows for drug profiling on membrane proteins embedded in their native environment. We enable drug screening programs against membrane proteins and other challenging therapeutic targets.

Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for the treatment of various cardiovascular diseases. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with cardiovascular diseases with vascular damages and inflammation. The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of Annexin A5. The production process is patented. ANXV has the ability to protect and repair the blood vessels as well as counteract the inflammation. ANXV is therefore expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major ones, such as heart attack. ANXV has the potential to become a First-In-Class drug (a product with new and unique mechanisms of action which is the first of its kind on the market) for several patient groups where there is considerable unmet demand for medical treatment.

Collabodoc AB is an innovative company that has developed a "light acute care"​ (Lättakuten) concept for Primary Care including a cloud based digital process tool. The Collabodoc concept has almost doubled the doctors'​ efficiency, increased the patients face-to-face time with the doctors, and reduced the administrative burden to a minimum. Several new products have just entered the market (digital contact tool, sick leave certificate tool) or are about to come soon (mental health tool, elective visit tool)... follow us to keep updated!

Peace of mind for the elderly, their relatives and caregivers - Aifloo was founded in 2015 with the vision of creating modern remote care system for the elderly which would deliver freedom, peace of mind and security to users, their relatives and caregivers. Today we are 20 people and our first system is on the market. We consider ourselves one of the most promising startups in the Nordics and have won many awards, along with support from the world class investors. We are a group of people with a mindset of providing real benefits to society through world class technologies. The thought of impacting society positively motivates us daily.

Thioredoxin Systems AB is a biotechnology company developing a novel antibiotic regimen against pathogenic bacteria. EbsArgent is a patented combination of ebselen and silver, capable of functioning as an antiseptic, antibacterial in food production, and as a medicinal product. With its versatility and ability to act on a wide range of multi-drug resistant bacteria, it is among the most promising antibiotic regimen under development today.

UU Invest är en tidig investerare med längre exitstrategi jämfört med många andra riskkapitalbolag. UU Invest bistår forskare och studenter att validera teknik, marknad och affärsmodell och investerar även i projekt innan bolagen är bildade. Ett samarbete med UU Invest innebär ett långsiktigt engagemang och tillgång till ett brett nätverk med kompetens och kapital. Genom UU Invest medverkar Uppsala universitet till att etablera nya forskningsbaserade företag. Sedan starten 1995 har UU Invest investerat över 100 MSEK i fler än 100 företag. Idag är UU Invest delägare i mer än 40 företag inom varierande branscher. English: UU Invest AB is an early investor that offers pre-seed and seed capital that makes it possible for researchers and entrepreneurs to further develop their research so that it can directly benefit society. With our early support, we contribute to the companys efforts to build the right business model, create a team with important skills and test their idea on the market. We invest long-term to give companies time to grow slowly, to develop their business and to build teams that can take cutting-edge expertise and technology further. Our involvement in the companies extends from the first investment to 5-15 years beyond.

Digitalizing Science to Improve Surgical Recovery Encare is a global leader in the implementation and continuous monitoring of ERAS® (Enhanced Recovery After Surgery) Protocols. Our mission is to transform scientific evidence into practical solutions that improve surgical outcomes, reduce variation in care, and optimize hospital performance. In partnership with the ERAS® Society, Encare provides: • The ERAS® Interactive Audit System (EIAS) — a digital platform for structured compliance tracking and continuous quality improvement. • The ERAS® Implementation Program (EIP) — a training program including a methodology for multidisciplinary change management and successful protocol adoption. ERAS® is a globally recognized standard of care that has been shown to: - Free up critical hospital resources and reduce overall costs - Reduce complications by up to 50% - Shorten hospital stays - Lower readmission rates - Improve staff satisfaction and long-term recovery Encare supports hospitals and healthcare systems in over 30 countries, helping them implement ERAS® Protocols with structure, consistency, and measurable results. With a proven track record of success, our solutions have contributed to significantly improved surgical outcomes and more efficient perioperative care across the globe. 🔗 Learn more: www.encare.net

At InSingulo, we specialize in the characterization of drug interactions with complex targets down to the single molecule level. Our biosensing technology allows for drug profiling on membrane proteins embedded in their native environment. We enable drug screening programs against membrane proteins and other challenging therapeutic targets.

Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for the treatment of various cardiovascular diseases. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with cardiovascular diseases with vascular damages and inflammation. The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of Annexin A5. The production process is patented. ANXV has the ability to protect and repair the blood vessels as well as counteract the inflammation. ANXV is therefore expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major ones, such as heart attack. ANXV has the potential to become a First-In-Class drug (a product with new and unique mechanisms of action which is the first of its kind on the market) for several patient groups where there is considerable unmet demand for medical treatment.